Savant Capital LLC Sells 954 Shares of Eli Lilly and Company (NYSE:LLY)

Savant Capital LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 41,650 shares of the company’s stock after selling 954 shares during the quarter. Savant Capital LLC’s holdings in Eli Lilly and Company were worth $24,278,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lipe & Dalton bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company during the third quarter worth $27,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company during the third quarter worth $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the third quarter worth $36,000. Finally, Family CFO Inc purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at about $40,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on LLY shares. Citigroup increased their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Truist Financial restated a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Barclays raised their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $731.55.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $44.36 during trading hours on Tuesday, reaching $781.56. The company had a trading volume of 7,432,651 shares, compared to its average volume of 3,071,009. Eli Lilly and Company has a 1-year low of $392.26 and a 1-year high of $800.78. The firm has a market cap of $742.61 billion, a PE ratio of 134.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The business’s 50 day moving average price is $760.89 and its 200-day moving average price is $668.00. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the company posted $2.09 EPS. The business’s quarterly revenue was up 28.1% on a year-over-year basis. Research analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.